Response to treatment series: part 1 and introduction, measuring tumor response--challenges in the era of molecular medicine.

[1]  Vahid Yaghmai,et al.  Response to treatment series: part 2, tumor response assessment--using new and conventional criteria. , 2011, AJR. American journal of roentgenology.

[2]  R. Simon,et al.  Stable Disease Is Not Preferentially Observed With Targeted Therapies and as Currently Defined Has Limited Value in Drug Development , 2009, Cancer journal.

[3]  D. Lebwohl,et al.  Progression-Free Survival: Gaining on Overall Survival as a Gold Standard and AcceleratingDrug Development , 2009, Cancer journal.

[4]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[5]  C Gatsonis,et al.  Validation of novel imaging methodologies for use as cancer clinical trial end-points. , 2009, European journal of cancer.

[6]  P. Heagerty,et al.  Survival Model Predictive Accuracy and ROC Curves , 2005, Biometrics.

[7]  Paul S Albert,et al.  Assessing surrogates as trial endpoints using mixed models , 2005, Statistics in medicine.

[8]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[9]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[10]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[11]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[12]  J C Lindsey,et al.  Tutorial in biostatistics methods for interval-censored data. , 1998, Statistics in medicine.